150 related articles for article (PubMed ID: 17005789)
1. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis.
Oyamada Y; Ito H; Inoue M; Yamagishi JI
J Med Microbiol; 2006 Oct; 55(Pt 10):1395-1401. PubMed ID: 17005789
[TBL] [Abstract][Full Text] [Related]
2. Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium.
Oyamada Y; Ito H; Fujimoto K; Asada R; Niga T; Okamoto R; Inoue M; Yamagishi JI
J Med Microbiol; 2006 Jun; 55(Pt 6):729-736. PubMed ID: 16687591
[TBL] [Abstract][Full Text] [Related]
3. [Genetical conditioning of fluoroquinolone resistance mechanisms of clinical enterococcus faecalis strains. II. The mutations present in the qrdrs of gyrA, gyrB, parC and parE genes].
Piekarska K; Jagielski M
Med Dosw Mikrobiol; 2007; 59(4):329-41. PubMed ID: 18416125
[TBL] [Abstract][Full Text] [Related]
4. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
Ruiz J; Sierra JM; De Anta MT; Vila J
Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
[TBL] [Abstract][Full Text] [Related]
5. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
8. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.
Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N
J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
10. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
12. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Nakase K; Sakuma Y; Nakaminami H; Noguchi N
Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
14. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
15. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
16. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of fluoroquinolone resistance.
Chen FJ; Lo HJ
J Microbiol Immunol Infect; 2003 Mar; 36(1):1-9. PubMed ID: 12741725
[TBL] [Abstract][Full Text] [Related]
19. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
[TBL] [Abstract][Full Text] [Related]
20. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Rafii F; Park M; Novak JS
Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
